Format

Send to

Choose Destination
See comment in PubMed Commons below
Clin Pharmacol Ther. 2014 May;95(5):499-500. doi: 10.1038/clpt.2014.38. Epub 2014 Feb 21.

Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing: 2014 update.

Author information

1
Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California, USA.
2
Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
3
Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA.
4
Department of Genetics, Stanford University, Stanford, California, USA.
5
Department of Clinical Pharmacy, University of California, San Francisco, San Francisco, California, USA.
6
Department of Pharmacology, University of Liverpool, Liverpool, UK.
7
Department of Pharmacy and Center for Personalized Healthcare, Cleveland Clinic, Cleveland, Ohio, USA.
8
Department of Medicine, Vanderbilt University, Nashville, Tennessee, USA.

Abstract

The Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for HLA-B Genotype and Abacavir Dosing were originally published in April 2012. We reviewed recent literature and concluded that none of the evidence would change the therapeutic recommendations in the original guideline; therefore, the original publication remains clinically current. However, we have updated the Supplementary Material online and included additional resources for applying CPIC guidelines to the electronic health record. Up-to-date information can be found at PharmGKB (http://www.pharmgkb.org).

PMID:
24561393
PMCID:
PMC3994233
DOI:
10.1038/clpt.2014.38
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley Icon for PubMed Central
    Loading ...
    Support Center